Pretomanid for tuberculosis treatment: an update for clinical purposes
Coronavirus disease (COVID-19) pandemic determined a 10 years-set back in tuberculosis (TB) control programs. Recent advances in available therapies may help recover the time lost. While Linezolid (LZD) and Bedaquiline (BDQ), previously Group D second line drugs (SLDs) for TB, have been relocated to...
| Published in: | Current Research in Pharmacology and Drug Discovery |
|---|---|
| Main Authors: | , , , , , , |
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2022-01-01
|
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590257122000487 |